封面
市场调查报告书
商品编码
1563400

人体生长荷尔蒙市场规模、份额、成长分析、按产品、按应用、按分销管道、按地区 - 产业预测,2024-2031 年

Human Growth Hormone Market Size, Share, Growth Analysis, By Product, By Application (Growth Hormone Deficiency, Turner Syndrome), By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年人体生长荷尔蒙的全球市场规模为55亿美元,从2023年的63.2亿美元成长到2031年的160.3亿美元,在预测期间(2024-2031年)预计将以复合年增长率增长。 %。

人体生长荷尔蒙(HGH)市场旨在解决生长激素缺乏症和相关疾病,如透纳氏症、普瑞德威利症候群和慢性肾臟病。这些疾病的日益普及以及患者和医疗保健提供者对 HGH 治疗益处的认识不断提高,推动了市场的发展。然而,治疗成本上涨、严格监管以及处方笺管理需求等挑战正在阻碍市场成长。儘管存在这些挑战,HGH 市场仍提供了机会,包括精准医学和个人化治疗、再生医学、荷尔蒙补充疗法的开拓、对老龄化相关疾病的持续研究以及可提高治疗效果的药物输送技术的进步。总体而言,HGH 市场在生长激素相关疾病的管理中发挥重要作用,并得到生物技术进步和意识不断提高的支持。

目录

介绍

  • 研究目的
  • 定义
  • 市场范围

调查方法

  • 资讯采购
  • 二手资料来源和主要资料来源
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 市场概况展望
  • 供需趋势分析
  • 按细分市场的机会分析

市场动态及展望

  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
  • 波特的分析

主要市场考察

  • 关键成功因素
  • 竞争程度
  • 主要投资机会
  • 市场生态系统
  • 价格分析
  • PESTEL分析

人体生长荷尔蒙市场:副产品

  • 市场概况
  • 长效
  • 其他的

人体生长荷尔蒙市场:依应用分类

  • 市场概况
  • 生长激素 (GH) 缺乏
    • 成人生长激素缺乏症
    • 儿童生长激素缺乏症
  • 透纳氏症
  • 原发性矮小症
  • 普瑞德威利症候群
  • 低出生体重儿
  • 其他的

人体生长荷尔蒙市场:按分销管道

  • 市场概况
  • 医院药房
  • 零售药房
  • 网路药房
  • 专业药房

人体生长荷尔蒙市场规模:按地区

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • 其他中东/非洲地区

竞争格局

  • 前5名企业对比
  • 主要企业市场定位(2023年)
  • 主要市场参与者所采取的策略
  • 近期市集活动
  • 主要企业市场占有率(2023年)

主要企业简介

  • Novo Nordisk A/S
  • Pfizer, Inc
  • Eli Lilly and Company
  • Sandoz International GmbH(Novartis AG)
  • Merck KGaA
  • Genentech, Inc(Roche)
  • Ferring Pharmaceuticals
  • Teva Pharmaceutical Industries, Ltd
  • Ipsen
  • GeneScience Pharmaceuticals
  • LG Chem
  • Anhui Anke Biotechnology Group
  • Biopartners
  • Endo International
  • Versartis
  • Opko Health
  • Rani Therapeutics
  • Somatopac
  • Hua'an Biological
  • Hangzhou Just Biotech
  • Shenzhen Hybio Pharmaceutical
简介目录
Product Code: SQMIG35I2308

Global Human Growth Hormone Market size was valued at USD 5.5 billion in 2022 and is poised to grow from USD 6.32 billion in 2023 to USD 16.03 billion by 2031, growing at a CAGR of 12.34% during the forecast period (2024-2031).

The human growth hormone (HGH) market aims to address growth hormone deficiencies and related disorders, including conditions like Turner syndrome, Prader-Willi syndrome, and chronic kidney disease. The market is driven by the increasing prevalence of these disorders and growing awareness among patients and healthcare providers about the benefits of HGH therapy. However, challenges such as the high cost of therapy, stringent regulations, and the need for prescription-based administration hinder market growth. Despite these challenges, opportunities abound in the HGH market, including the development of precision medicine and personalized treatments, ongoing research into regenerative medicine, hormone replacement therapy, and age-related disorders, and advancements in drug delivery technologies that enhance treatment outcomes. Overall, the HGH market plays a crucial role in managing growth hormone-related disorders and is supported by advancements in biotechnology and increasing awareness.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Growth Hormone market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Growth Hormone Market Segmental Analysis

Global Human Growth Hormone Market is segmented by Product, Application, Distribution Channel and region. Based on Product, the market is segmented into Long Acting, Others. Based on Application, the market is segmented into Growth Hormone (GH) Deficiency (Adult GH Deficiency, Pediatric GH Deficiency), Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small For Gestational Age, Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Drivers of the Global Human Growth Hormone Market

The rising prevalence of growth hormone-related disorders, including growth hormone deficiency and genetic conditions, is fueling the demand for HGH therapy. In 2022, heightened awareness and improved diagnostic capabilities led to more patients seeking treatment. According to the European Society for Paediatric Endocrinology (ESPE), there was a notable increase in the incidence of growth hormone deficiency among children in Europe during that year. This surge in cases has driven a greater need for HGH therapy to address growth hormone-related issues in affected children.

Restraints in the Global Human Growth Hormone Market

The high costs associated with HGH treatment can create significant barriers to access for some patients and healthcare systems. A 2022 study published in a medical journal underscored the financial strain that both patients and healthcare providers experience due to the steep price of HGH therapy. This highlighted the urgent need for more cost-effective solutions and potential pricing reforms to improve accessibility to HGH treatment.

Market Trends of the Global Human Growth Hormone Market

Physicians and researchers are increasingly prioritizing personalized HGH therapy, considering individual patient characteristics such as genetic factors and specific medical conditions. In 2022, a clinical trial was launched to assess the effectiveness of personalized dosing regimens for HGH therapy in children with growth hormone deficiency. The goal of this trial was to determine the advantages of tailored treatment approaches in enhancing growth outcomes.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factor
  • Degree of Competition
  • Top Investment Pockets
  • Ecosystem of the Market
  • Pricing Analysis
  • PESTEL Analysis

Human Growth Hormone Market, By Product

  • Market Overview
  • Long Acting
  • Others

Human Growth Hormone Market, By Application

  • Market Overview
  • Growth Hormone (GH) Deficiency
    • Adult GH Deficiency
    • Pediatric GH Deficiency
  • Turner Syndrome
  • Idiopathic Short Stature
  • Prader-Willi Syndrome
  • Small For Gestational Age
  • Other

Human Growth Hormone Market, By Distribution Channel

  • Market Overview
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Specialty Pharmacy

Human Growth Hormone Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Novo Nordisk A/S
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer, Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sandoz International GmbH (Novartis AG)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genentech, Inc (Roche)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ferring Pharmaceuticals
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries, Ltd
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ipsen
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GeneScience Pharmaceuticals
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • LG Chem
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Anhui Anke Biotechnology Group
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biopartners
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Endo International
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Versartis
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Opko Health
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Rani Therapeutics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Somatopac
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hua'an Biological
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hangzhou Just Biotech
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shenzhen Hybio Pharmaceutical
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments